Browse by Audience
Skip to content
Papers of the Week
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.
Abstract
Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to be safe and efficacious for the preventive treatment of chronic migraine based on the randomized, placebo-controlled double-blind period of the REGAIN study (Clinicaltrials.gov identifier: NCT02614261). Long-term safety and efficacy were assessed in an open-label extension.